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Given the increased life expectancy of human immunodeficiency virus (HIV) infected individuals treated with combination
antiretroviral therapy (cART) and the ongoing inflammation observed in the brains of these patients, it is likely that
premature neurodegeneration as measured by phospho-tau (p-tau) or increased total tau (t-tau) protein may become
an increasing problem. This review examines the seven human studies that have occurred over the past 14 years
measuring p-tau and/or t-tau in cerebrospinal fluid (CSF) or via post-mortem brain immunohistochemistry. Although
not all studies are in agreement as to the changes in p-and t-tau in HIV infected patients, HIV persists in the brain
despite cART. Thus is it is suggested that those maintained on long-term cART may develop tau pathology beyond
the extent seen in the studies reviewed herein and overtime may then reach the threshold for clinical manifestation.
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HIV-associated neurocognitive disorders (HAND)
More than 33 million people worldwide are infected
with the human immunodeficiency virus (HIV) [1].
HIV-1 infection of the central nervous system (CNS)
can result in cognitive, motor, and behavioral deficits,
collectively termed HAND [2,3]. These deficits present
along a spectrum from asymptomatic neurocognitive
impairment (ANI) to HIV associated dementia (HAD).
The latter is also termed HIV associated dementia
complex (HADC), AIDS dementia complex (ADC), or
HIV-encephalitis (HIVE; a diagnosis which can be
made only upon brain autopsy exam) depending on
the research report [3]. Soon after infection by the HIV, it
rapidly moves into the brain via infected monocytes and
lymphocytes [4] and, despite combination antiretroviral
therapy (cART), persists in parenchymal microglia as well
as the perivascular macrophages [5-7]. As HIV is unable
to productively infect neurons, neuronal cell damage
is largely promoted by neurotoxins secreted by these
infected and/or activated macrophages, microglia, and* Correspondence: bgiunta@health.usf.edu
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unless otherwise stated.astrocytes [5]. In spite of the fact that the clinical
severity of HAND has been significantly reduced due
to the widespread utilization of cART, the prevalence
and associated morbidity still remains high (~50% [8,9]).
Why HAND still persists in the current era of cART, even
in patients effectively controlled for systemic viremic load,
is incompletely understood. Recent evidence suggests
prolonged inflammation in both the brain and periphery
may be responsible [10-13].
Chronic HIV infection promotes neuroinflammation
and leads to neuronal death and damage [14]. In addition,
it has been reported that subjects treated with com-
bination cART have high levels of neuroinflammation,
especially in the hippocampus [13,15]. This type of neu-
roinflammation in the form of microglial activation is
associated with a number of neurodegenerative diseases
including Alzheimer’s disease (AD), Pick’s disease, and
hereditary frontotemporal dementia with Parkinsonism
linked to chromosome 17 (FTDP-17) [16,17].
Since the introduction of cART the neuropathology
associated with HIV has changed. The prevalence of some
opportunistic conditions including Cytomegalovirus and
toxoplasmosis has decreased while that of others such as
progressive multifocal leucoencephalopathy and lymph-
oma appears to have not changed [15,18,19]. The effect of
cART on neurocognitive decline and dementia is, on the
other hand, less clear, despite a reduced prevalence of theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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report improved cognitive function in cART-treated
individuals [20-24], others suggest cognitive impairment
is still a significant clinical problem [9,24-32].
Regardless of the effects of cART directly on HAND,
HIV patients who are given this therapy are now living
much longer. As humans age, HIV infected or not, there
is an increase in the prevalence of signs of neurodegen-
eration [33] even in otherwise healthy individuals [34].
Since 2000 there has been an array of reports suggesting
the possibility of advanced brain aging in the form of
AD-like pathology in HIV patients [35-40]. Most of the
recent literature indicates that there is an increased
risked of advanced brain aging but perhaps not in the
exact pattern of true AD. Rather the reports signal an
increase in certain, but not all forms of the key proteins of
AD, amyloid-beta (Aβ) and tau. This review focuses on
tau protein and begins to identify what influence both
chronic HIV infection and long-term cART will have on
the process of advanced brain aging in the form of abnor-
mal tau pathology and associated functional deficits.
Tau protein
Central to the formation and subsequent stabilization
of microtubules as well as the movement of organelles
along axons and dendrites, tau is a microtubule-associated
protein which is largely expressed in central nervous
system (CNS) neurons [41]. Inflammatory stimuli can
facilitate tau phosphorylation [42-44] although it remains
unclear where phosph-tau is the cause, result, or merely
an correlation with inflammation. The hyperphosphory-
lation of tau has been associated with neurodegeneration
[45-47]. Further, hyperphosphorylated tau (p-tau) can
undergo cellular accumulation leading to the formation
of insoluble neurofibrillary tangles (NFTs) and neuropil
threads [48] and thus in some transgenic models of AD,
deletion of tau is protective [49,50].
In very young healthy individuals hyperphosphorylated
tau is not commonly detected [51]. It has been reported
that by the age of 55, half of individuals show some
evidence of tau in the entorhinal cortex (EC) [51]. In
these early stages, hyperphosphorylated tau is usually
only found in the EC in non-demented individuals. By the
age 75, almost all brains contain some hyperphosphory-
lated tau which has spread to involve the hippocampus
(CA1) and neocortex. It should be noted however that tau
accumulation is not an inevitable consequence of ageing
since studies have identified extremely old, non-demented
individuals with only mild tau pathology at autopsy [52].
Although a full understanding of any pathophysiological
importance of increased tau (t-tau) is not yet established,
it is seen in AD and to a lesser extent in vascular
dementia and other neurodegenerative disorders [53].
Therefore, given the increased life expectancy of HIV-infected individuals treated with cART and, age being a
major risk factor for increased phospho-tau, it likely that
premature brain ageing as measured by p-tau or increased
t-tau protein may become an increasing problem.
Epidemiology of Tau protein in HIV infection
Over the past 14 years there have been several epidemio-
logical studies examining cerebrospinal fluid (CSF) and
post- mortem brain samples for changes of p-tau or t-tau
in HIV infected patients (Table 1, Figure 1). Some studies
have taken cART into account [39,54-57] while others
have not [35,37]. A study by Green and colleagues pro-
spectively measured CSF t-tau in 76 consecutive HIV
infected patients who had acute neurological episodes.
Twenty four patients had HADC, 10 had lymphoma, 20
had cerebral infections; 22 patients had miscellaneous
conditions, including nine with self-limiting headache/
fever [35]. The subjects had a median age of 37 years.
Past history of cART was not taken into account. CSF
tau levels were acquired by enzyme linked immuno-
sorbent assay (ELISA) (INNOTEST, Fujirebio Europe/
Innogenetics, Ghent, Belgium) [58] with an upper limit
of normal in CSF set at 315 pg/ml and a lower limit of
detection set at 75 pg/ml (Table 1). Results indicated
CSF tau was not elevated in the majority (62/76) (82%)
of patients, regardless of their CD4 lymphocyte count
or their clinical diagnoses. Elevated CSF t-tau was sig-
nificantly associated with poor outcome as six of eight
patients who died within 4 weeks of lumbar puncture
had elevated t-tau [35].
Subsequently there was an analysis of the prevalence
of CSF t-tau and p-tau concentrations from 101 HIV-1
seropositive individuals, some of whom had ADC [37].
The CSF from 20 patients with moderate to severe AD
was used as a positive control [37]. CSF from 20 patients
not known to have HIV or AD was also analyzed. CSF
t-tau was quantified using an hTau antigen assay, and
p-tau concentrations were determined using a Phospho-
Tau181 (p-tau181) assay that recognizes the p-Tau at
Threonine-181. Both were measured using the Innotest
ELISA with lower limits of 75 and 16 pg/mL. They found
HAND subjects had significantly increased t-tau and
p-tau at concentrations similar to patients with AD,
suggesting that ADC may be associated with an AD-like
process [37]. Overall, CSF t-tau levels were significantly
increased in ADC Stage 2 while CSF p-tau levels were
significantly increased in each of the ADC stages com-
pared with the negative controls and the AD patients. The
authors noted that these data indicate patients with ADC
have significantly increased t-tau and p-tau concentrations
which are of the same magnitude as found in AD patients
[37]. In eight ADC patients (mean age 43 years), CSF t-tau
was increased [37]. This is in contrast to the previous
study by Green and colleagues [35] where 24 ADC
Table 1 Epidemiological studies of p-tau and t-tau in HAND
Author,
Year
Study Subjects Technique used Tau detection
range (pg/ml)













t-tau: 75-316 1) CSF tau not elevated in 82% of patients,
regardless of clinical diagnoses.
2) N = 76 (24-HAD, 10 lymphoma, 20
cerebral infarctions, 22 miscellaneous
conditions such as headache)
2) Elevated CSF tau was associated with
poor outcome as 6 of 8 patients who
died within 4 weeks of lumbar puncture.
3) cART not accounted for
Brew
et al. [37]
CSF amyloid beta42 and
tau levels correlate with
AIDS dementia complex
1) Mean age: 43 years ELISA (INNOTEST, Fujirebio
Europe/Innogenetics,
Ghent, Belgium)
Upper limits not reported wer
limits: t-tau: 75, p-tau:16
1) HAND subjects had significantly
increased t-tau and p-tau at residue
181 (p-Tau181) at concentrations
similar to patients with AD
2) N = 101 HIV positive subjects with
or without ADC with 20 moderate to
severe AD subjects as positive control
2) p-tau levels significantly increased
in all of the ADC stages compared
with the negative controls and the
AD patients.




in the brains of individuals
infected with human
immunodeficiency virus-1
before and after the advent
of highly active anti-retroviral
therapy
1) Mean age: 40 for HIV- control group
and HIV positive cases, 70 for HIV
negative control group and 40 for
HIV negative control group B
Immunohistocytochemistry
(TSA was used in instances
where avidin-biotin complex
ABC was not sensitive enough,
with DBA for visualization.)
NA: AT8 antibody used
on paraffin sections
1) Higher levels of p-tau in HIV
infectedsubjects vs. aged
matched controls.
2) N = 34 2) Greatest levels of p-tau were
noted in cART-treated subjects.
3) Nine cART treated subjects with
excellent compliance for at least
18 months with pre-symptomatic HIV
or AIDS and 20 pre-cART HIV subjects
3) Increased t- tau in hippocampal
region of pre-cART HIV-infected




CSF biomarkers of Alzheimer
disease in HIV-associated
neurologic disease
1) Mean age: normal cognition control
group (50 years), HIV + normal cognition
(43 years), HAND subjects (48 years),




Not reported HIV-positive subjects with HAND
did not have CSF t-tau and p-tau181
characteristic of AD
2) N = 188 (50 control, 68 AD subjects,
21 Neuro-normal HIV positive subjects
and 49 HAND subjects.




Increased CDK5 expression in
HIV encephalitis contributes
to neurodegeneration via tau
phosphorylation and is reversed
with Roscovitine
1) Mean age: HIVE patients - 43.13 years,
Non HIVE subjects (48.38 years )
Immunohistochemistry N/A:AT8 and PHF-antibod
detection on post-mortem ain
Elevated diffuse nonfibrriliar p-tau in
HIVE group and HIV gp120 tg mice.
2) N = 16: 8 HIVE subjects, 8 HIV
positive without HIVE
(TSA was used in instances
where avidin-biotin complex
ABC was not sensitive enough,

























HIV infection is associated
with MRI and CSF pattern
of neurodegeneration
1) Mean age: 45 ± 10 years ELISA (INNOTEST, Fujirebio
Europe/Innogenetics,
Ghent, Belgium)
Not reported 1) Significant correlation between
HAND and t-tau but not p-tau
2) N = 94. All patients were HIV
positive with varying levels of
neuropsychological performance,
2) HAND severity correlated
significantly with the t- tau level
in CSF but not p-tau levels








1) Mean age: 45.8 years for
HIV+, 42.2 years for HIV-
Immunohistochemistry NA: AT8 on
post-mortem brain
1) IDU had more t- tau vs. non-DU
2.) N = 20 :10 HIV + (6 IDU,
4 non-IDU),10 HIV (6 IDU,
4 non-IDU)
(TSA was used in instances
where avidin-biotin complex
ABC was not sensitive enough,
with DBA for visualization.)
2) HIV + subjects had more t-tau
than HIV -, but these differences did
not achieve statistical significance.
3) HIV + patients treated



















Figure 1 Synopsis of clinical studies examining the relationship between tau and HIV infection and/or HAND.
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5 with increased levels. One explanation for these conflict-
ing results relates to the age of the patients [35] and this
confounder also occurs in other studies in this review. In
general studies indicating CSF t-tau concentrations that
were increased were composed of older individuals (mean
age of 43 years or older). Conversely those with negative
results had a younger mean age, in this case [37] approxi-
mately 37 years. The study by Green and colleagues [35],
did show a non-significant trend to higher values in those
patients 40 years of age and older. Furthermore, Green
and colleagues study [35] likely included more subjects
with more severe ADC because which is in agreement
with the results of Brew and colleagues who showed a
relationship to Stage 2 ADC [37] (Table 1).
Following, there was an investigation into investigated
the prevalence of tau-associated neurodegeneration in
nine cART-treated individuals who had a history of
excellent therapeutic compliance for at least 18 months
and compared 20 pre-cART HIV-infected subjects and
14 control cases [54]. The pre-cART groups included:
pre-symptomatic HIV-positive and AIDS cases. The nine
cART-treated cases had a history of excellent therapeutic
compliance for at least 18 months. Two groups of
HIV-negative control cases with no CNS pathology
were selected to provide a baseline. The first group
was age matched (mean age 40) with the HIV cases
while the second group represented older individuals(mean age 70) who had no history of cognitive decline
or other neurodegenerative disorder. This older group
allowed for analyzing the extent of any premature ageing
effect in a much younger HIV cohort. Paraffin blocks
of hippocampus and pons were selected for each case.
Immunohistochemistry was performed using AT8 anti-
body, which recognizes p-tau at serine 202. Tyramide
signal amplification (TSA) was used to enhance staining in
experiments because the standard avidin-biotin complex
(ABC) techniques were not sensitive enough for several of
the antibodies. Diaminobenzidine (DAB) was then used to
visualize all antibodies. Results of this study showed higher
levels of p-tau in the EC, hippocampus, and neocortex in
HIV infected subjects compared to aged matched controls.
Interestingly, the greatest levels of p-tau were noted in
cART-treated subjects. Increased levels of t-tau were also
seen in the hippocampal region of pre-cART HIV-infected
groups compared to HIV-negative age-matched controls
[54]. The increases in tau were independent of a history of
drug abuse, although the number of cases studied in each
group was low when subdivided into drug abusers and
non-drug abusers. This is interesting given past finding of
increased levels of p-tau in young HIV-negative drug
abusers (mean age 27) [59]. The group of pre-symptomatic
subjects studied were all HIV-positive drug abusers and
therefore in this group it was not possible to determine
whether p-tau levels were increased compared to controls
as a result of drug abuse, as reported by Ramage et al.,
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responsible. No evidence of significant head injury in
patients’ life history or on routine neuropathological
examination was found and it was thus conclude that
head injury was unlikely to be a contributing factor in
the observed tau pathology [54]. The authors note that
if two control groups represent different ends of the
spectrum of normal deposition of hyperphosphorylated tau
in non-demented individuals, then these results suggest
that HIV-infected individuals have shifted significantly
away from normal age-matched controls towards the
levels seen normally in ‘old age’ [54]. This would suggest
these individuals are subject to advanced brain aging,
which is of particular concern in the cART-treated
group and may promote future HAND [33]. Thus those
maintained on long term cART may develop tau pathology
beyond the extent seen in this study and that this may
then reach the threshold for clinical manifestation [54].
Clifford and colleagues [39] examined CSF from a total
of 188 subjects clinically categorized with normal cogni-
tion from the general population (mean age 50 years),
HIV + subjects with normal cognition (mean age 43 years),
HIV + subjects with impaired cognition (mean age 48),
or presumed HIV − subjects with mild AD (mean age
74). CSF samples were analyzed for t-tau, and p-tau by
ELISA (INNOTEST, Fujirebio Europe/Innogenetics, Ghent,
Belgium), however, upper and lower limits of detection
were not supplied in the report. In contrast to Brew and
colleagues [37], HIV-positive subjects with HAND did not
have CSF t-tau and p-tau characteristic of AD however, this
report in congruence with Brew and colleagues analyses
in which also indicates t-tau was significantly elevated
in CSF of this HIV positive population versus non-HIV
infected subjects [37]. Overall there was a trend for
HAND patients to have higher p-tau and t-tau than
HIV positive non-HAND patients. It is notable that this
report of non-significantly elevated p-tau in the AD
patients is also not in agreement with the AD literature.
Using both an epidemiological approach to identify
tau pathology in HIV infection, and then modeling this
phenomenon in vivo can lead to useful prevalence and
mechanistic data regarding the influence of abnormal
tau on HAND. Patrick and colleagues [55], using double
labeled using the Tyramide Signal Amplification-Direct
(Red) system (NEN Life Sciences, Boston, MA). Using
this system, FITC tagged p-tau immunohistochemistry
antibodies: AT8 and PHF-1 were analyzed, in the brains
of 43 patients with HIVE (median age 43.13 years) and
in gp120 Tg mice, showing that increased expression of
cyclin-dependent kinase 5 (CDK5) can lead to neurotox-
icity via promotion of abnormal tau phosphorylation.
Researchers utilized FITC tagged manufactured p-tau
immunohistochemistry antibodies: AT8 (Ser 202) and
PHF-1, which detects p-tau at Ser396 and Ser404.Subjects were excluded if they had a history of CNS
opportunistic infections or non-HIV-related developmen-
tal, neurological, psychiatric, or metabolic conditions that
might affect CNS functioning. For inclusion, a total of 16
age-matched cases were identified with and without
encephalitis or other complications. cART status was
not taken into account. Overall the resulting data are
consistent with other studies indicating aberrant activation
of the CDK5 [60,61] and glycogen sythanse kinase (GSK)
3β [60,62-65] signaling promoting neurodegenerative
changes in HAND patients. The p25/CDK5 complex
associates with NFT in AD patients [66], and CDK5 has
been shown to abnormally phosphorylate tau [67]. These
are recognized by the AT8 and PHF-1 antibodies [68].
Both of these phosphorylation epitope-specific tau anti-
bodies were elevated in patients with HIVE and in gp120
Tg mice. The patterns of AT8 and PHF-1 immunostaining
in HIVE patients differed from what has been reported in
AD patients. That is, in advanced AD cases the p-tau
immunoreactivity is associated with dystrophic neurites,
neuropil threads, and NFT [69-73]. On the other hand
in the HIVE cases and in gp120 Tg mouse model there
was diffuse nonfibrillar p-tau immunostaining detected
in neurons and throughout the neuropil. Increased
CDK5 and p35/p25 immunoreactivities were also detected
throughout the neuropil of HIVE brains and gp120 Tg
mice, indicating the expression of these proteins in
cellular compartments that extend into the dendritic
arbor and synapses. Data on whether the patients were
on cART was not provided. The diffuse pattern of p-tau
immunostaining was similar to what has been described
in patients with preclinical AD or in the pretangle stage
[70,74], suggesting that in HIVE some of the initial trig-
gering events are present [55] which is in agreement with
the previous study by Anthony et al. [54] and suggests
HIV patients, whether on cART or not, may develop tau
pathology beyond the extent seen at the age relatively
young ages of the patients of these studies and that tau
pathology may reach the threshold for clinical manifest-
ation as the aging process continues [54].
A recent cross-sectional investigation examined 94
patients (mean age 45 ± 10 years) via CSF analysis for
t-tau and p-tau [56]. This study only enrolled patients
who never received cART because of unimpaired immune
state or who were taking their first cART regimen. In
total, 68% of the cohort was cART-treated. Seventy-two
percent (72%) of the patients with cART were virologically
suppressed. Upper and lower limits of detection were not
supplied for the t-tau or p-tau ELISA assays (INNOTEST,
Fujirebio Europe/Innogenetics, Ghent, Belgium). Patients
with signs of opportunistic CNS infection by MRI or CSF
analysis were excluded from further analysis as well as
those with psychiatric disorders or severe impairment
of consciousness. A significant correlation between
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Interestingly HAND severity as measured by the Memor-
ial Sloan-Kettering scale, HIV dementia scale and Mosaic
test correlated significantly with the total tau level in CSF
but not p-tau levels [56]. Although measures of global
brain atrophy via MRI in this study did not significantly
correlate with the increase in t-tau, the results suggest t-
tau might be a non-specific marker of ongoing subcortical
CNS damage particularly in the region of the periventricu-
lar white matter and the basal ganglia in HIV infection.
A most recent study by Smith et al. [57] examined p-tau
in ten HIV positive and ten HIV negative subjects. A
portion of both groups were IDU. All HIV positive
patients had been treated with cART for up to 7.9 years
and most had received Zidovudine before the start of
cART. Cases with opportunistic infections or tumors in
the brain were excluded from this study. All six HIV
positive IDU, but only one HIV positive non-DU, were
HCV positive while the HIV negative IDU and non-IDU
were all HCV-negative. Using the AT8 (Ser202) antibody
as the primary method for tau quantification, the results
revealed declining positivity for tau (neuropil threads and
NFT) across all four groups, with IDU having more tau
than the non-DU and HIV positive subjects more than
HIV negative, but these differences did not achieve statis-
tical significance. A likely reason for the non-significance
may be that the study was underpowered [57].
Conclusion
Together, this review suggests that the measurement of
t-tau and p-tau in CSF maybe a useful tool for monitor
HAND risk at relatively young ages, or for predicting
prognosis in later ages (Table 1). Though differing methods
of tau quantification were utilized across a portion of the
reviewed reports, the research is beneficial in emphasizing
the relationship between the presence of t-tau and p-tau in
the brain or CSF and the patient’s HAND status. Because
of the aging of the HIV-positive population, this biomarker
may well be of increasing utility. Although the incidence of
HAD has decreased with the widespread use of cART,
patients continue to experience varying degrees of HAND
[75]. Since even mild impairment affects quality of life
[76], the neurological consequences of HIV infection
have gained increased attention, as has the need to
distinguish those at risk for impairing neurodegenera-
tion through dynamic changes in tau. Future studies
with larger numbers of patients across a wider age
range may fine-tune this suggested form of evaluation
for HAND risk and as a possible treatment target.
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